More Articles

Biosimilars applications reviewed in the EU Biosimilars/Research | Posted 04/10/2019

The European Union (EU) was the first to establish a legal framework for biosimilars back in 2003 [1]. Since the European Medicines Agency (EMA) approved its first biosimilars in 2006, the agency h...

Three darbepoetin alfa biosimilars approved in Japan Biosimilars/News | Posted 04/10/2019

Three pharmaceutical companies have announced approval of their anaemia treatments for sale on the Japanese market, while Mochida reveals it will sell the first teriparatide biosimilar in the country.

Novo Nordisk to launch biosimilar insulin in the US Biosimilars/General | Posted 04/10/2019

Novo Nordisk has announced plans to launch biosimilar versions of its NovoLog and NovoLog Mix insulin products in the US in January 2020.

iBio and CC-Pharming collaborate for rituximab copy biological in China Biosimilars/News | Posted 04/10/2019

Biotechnology company iBio, self-professed leader in the plant-made pharmaceutical field, announced on 27 August 2019 that it will expand its collaboration with China-based CC-Pharming for a rituxi...

Switching from originator to biosimilar epoetins appears to be effective and safe Biosimilars/Research | Posted 04/10/2019

Switching between biological drugs during pharmacological treatment leads prescribers and patients to ask themselves the question: ‘Will it be safe?’. In particular, when switching from an originat...

New evidence: comparable clinical outcomes for generic and brand medications Generics/Research | Posted 04/10/2019

New research carried out at Brigham and Women’s Hospital and Harvard Medical School, provides additional evidence that shows generic and brand-name drugs have comparable clinical outcomes [1].

Celltrion contracts Lonza to manufacture autoimmune treatment Remsima Pharma News | Posted 04/10/2019

South Korean biosimilars manufacturer Celltrion have announced a deal with Swiss contract manufacturing organisation (CMO) Lonza to produce its autoimmune biosimilar Remsima at a facility in Singap...

Carcinogen contamination halts distribution of generic Zantac Generics/General | Posted 04/10/2019

Heartburn drug Zantac (ranitidine) is being taken off markets worldwide following findings that the medications may be contaminated with cancer-causing agents.